• Join
  • Login
  • Contact

Search abstracts

Regulatory Perspective on Drug Safety Assessment during Drug Development

  • At: Stockholm (Sweden) (2017)
  • Type: Presentation
  • By: SATO, Masanobu (Pharmaceuticals & Medical Devices Agency, Tokyo, Japan)
  • Co-author(s): Masanobu Sato: Pharmaceuticals & Medical Devices Agency, Tokyo, Japan
  • Abstract:

    One of the major concerns when conducting evaluation of a new drug at the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan is whether there are any unacceptable risks as compared to the benefit.  A comprehensive evaluation on drug safety should be conducted considering whether the recognized risks in clinical studies can be controlled,


  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses